Cite
HARVARD Citation
Kawakita, D. et al. (2022). Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. Therapeutic advances in medical oncology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kawakita, D. et al. (2022). Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. Therapeutic advances in medical oncology. p. . [Online].